Personalized Chimeric Antigen Receptor T Cell Immunotherapy for Patients With Recurrent Malignant Gliomas

Inclusion Criteria: * Voluntary informed consent for entry of trial; * Age greater than 18 years, and less than 70 years; * Pathologically confirmed recurrent malignant gliomas; * Tumor cells from resected tissue must be available for antigen testing (EGFRvIII, IL13Rα2, Her-2, CD133, EphA2, GD2) and at least one of the targets should be tested positively by immunohistochemistry study; * If the patient is on dexamethasone, the anticipated dose must be 4 mg/day or less for at least 5 days prior to apheresis. * Patients must have a Karnofsky performance status of greater than or equal to 70. * Life expectancy greater than 3 months; * Participants with adequate organ function as measured by: 1. White blood count greater than or equal to 2500/mm\^3; platelets greater than or equal to 100,000/mm\^3, hemoglobin greater than or equal to 10.0 g/dL; without transfusion or growth factor support 2. Aspartate transaminase (AST), Alanine transaminase (ALT), gamma glutamyl transpeptidase (GGT), lactic acid dehydrogenase (LDH), alkaline phosphatase within 2.5 x upper normal limit, and total bilirubin less than or equal to 2.0 mg/dL 3. Serum creatinine less than or equal to 1.5 x upper limit of normal 4. Coagulation tests prothrombin time (PT) and partial thromboplastin time (PTT) have to be within normal limits, unless the patient has been therapeutically anti-coagulated for previous venous thrombosis. Exclusion Criteria: * Female subjects of reproductive potential who are pregnant or lactating; * Previous treatment with any gene therapy products or other form immunotherapy; * Uncontrolled active infection. * Active or latent chronic hepatitis B \[detectable hepatitis B surface antigen (HBsAg)\] or active hepatitis C (positive serology \[hepatitis C virus Ab\]) infection. * HIV infection; * History of allergy or hypersensitivity to study product excipients (human serum albumin, Dimethyl sulfoxide, and Dextran 40); * Currently enrolled in other clinical trials;